Australia's Bioxyne hits five-month high on commercialising psilocybin capsules

BLS Pharmaceuticals

11/02/2026 03:47

** Shares of Australia's Bioxyne BXN.AX rise 6.7% to A$0.048, their highest since September 4

**  Wellness and pharmaceutical co secures initial purchase orders of psilocybin capsules in Australia

** Co says the capsules are intended for investigational use in depression and exploratory research into other mental health conditions

** Stock up 14.3% YTD

 (Reporting by Shruti Agarwal in Bengaluru)

 ((Shruti.Agarwal@thomsonreuters.com))